Sign In
Buy RLY
$36.80
-0.110 (-0.298%)
At Close: Jun 03, 2026
5 ETF Picks for April
02:00pm, Tuesday, 08'th Apr 2025
Bet on defensive and high-earnings growth sectors in this tumultuous April.
6 Trade-Resilient ETFs for Investors
09:40am, Thursday, 03'rd Apr 2025
The S&P 500 has been under pressure due to trade tensions. These ETFs look trade-proof.
Relay Therapeutics: A Precision Oncology Play Worth The Risk
02:17am, Friday, 14'th Feb 2025
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
Company to host conference call on Wednesday, December 11, 2024 at 7am ET Company to host conference call on Wednesday, December 11, 2024 at 7am ET
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
04:57pm, Monday, 16'th Sep 2024
Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast c
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
08:15am, Wednesday, 11'th Sep 2024
Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-m
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
06:55am, Monday, 09'th Sep 2024
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Fav
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
04:05pm, Friday, 06'th Sep 2024
Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday, Septembe
RLY: A Nice Allocation Fund
05:13pm, Thursday, 06'th Jun 2024
Asset allocation is still important despite recent performance trends. SPDR® SSgA Multi-Asset Real Return ETF offers a mix of asset class exposure for real returns. The RLY ETF focuses on inflation-p
RLY: More Of A Cyclical Play Than A Portfolio Diversifier
03:54pm, Thursday, 14'th Mar 2024
RLY: More Of A Cyclical Play Than A Portfolio Diversifier
RLY: Multi-Asset ETF Beating Peers For 3 Years
05:40pm, Friday, 08'th Dec 2023
SPDR® SSgA Multi-Asset Real Return ETF is an actively managed fund of funds aiming at excess return over inflation. The RLY fund provides exposure to inflation-protected securities, real estate secur
RLY: Still A Good Idea
01:15pm, Saturday, 16'th Sep 2023
Inflation has cooled but may rise again in the future, making an investment in a real asset ETF like RLY a smart idea. TIPS have not performed well as an inflation hedge due to rising real interest ra
RLY Remains An Effective Inflation Hedge, But Is Not A Buy Under Current Conditions
03:16am, Tuesday, 07'th Feb 2023
RLY invests in a diversified portfolio of inflation-hedge ETFs. The fund tends to outperform when inflation is high, underperform when it is low.
RLY: Own This If Inflation Makes A Comeback
10:10pm, Thursday, 02'nd Feb 2023
RLY provides exposure to natural resource equities, commodities, and infrastructure assets that should do well in an inflationary environment. In recent months, headline inflation has eased, prompting
